Last €2.07 EUR
Change Today +0.032 / 1.57%
Volume 1.1M
SRN On Other Exchanges
As of 11:30 AM 01/28/15 All times are local (Market data is delayed by at least 15 minutes).

sorin spa (SRN) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/6/14 - €2.35
52 Week Low
10/15/14 - €1.63
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for SORIN SPA (SRN)

Related News

No related news articles were found.

sorin spa (SRN) Related Businessweek News

No Related Businessweek News Found

sorin spa (SRN) Details

Sorin S.p.A. develops, produces, and distributes medical devices for cardiac surgery and for the treatment of cardiac rhythm dysfunctions. It offers disposable biomedical devices and systems, including heart-lung machines; cardiopulmonary systems, such as oxygenators and custom packs; autotransfusion systems and disposables; perfusion tubing systems; cannulae; and endoscopic vessel harvesting systems for extracorporeal circulation during surgery. The company also provides mechanical heart valves, tissue heart valves, self-anchoring tissue heart valves, and annuloplasty rings to replace or repair dysfunctional heart valves or treat congenital diseases. In addition, it offers implantable devices, monitoring systems, and accessories to treat cardiac rhythm dysfunctions that comprise pacemakers, implantable defibrillators, systems to treat heart failure (CRT-D), programmers, electrodes, electrophysiology leads, and Holter monitors; and disposable medical devices for urology, urodynamics, heart surgery, and haemodialysis. The company sells its products worldwide primarily under the Sorin Biomedica, Dideco, Stöckert, Cobe Cardiovascular, Ela Medical, and Carbomedics brand names. Sorin S.p.A. was founded in 2004 and is headquartered in Milan, Italy.

3,814 Employees
Last Reported Date: 10/30/14
Founded in 2004

sorin spa (SRN) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: €789.0K
Chairman, President and Chairman of Executive...
Total Annual Compensation: €629.0K
Compensation as of Fiscal Year 2013.

sorin spa (SRN) Key Developments

Sorin Group Announces the Completion of Patient Enrollment for Perceval IDE Study in USA

Sorin Group announced completion of US enrollment of the Perceval Investigation Device Exemption (IDE) Trial. The trial enrollment was completed on schedule with the implantation of 300 patients. The IDE study is designed as a prospective, non-randomized, multi-center clinical trial. The purpose of this study is to demonstrate the safety and effectiveness of the Perceval valve when used to replace diseased or dysfunctional aortic valves or aortic valve prostheses. The patients enrolled in the US IDE study were all adult patients suffering from aortic valve stenosis or steno-insufficiency, indicated for native or prosthetic aortic valve replacement and available for postoperative follow-up beyond one year. In total, eighteen centers across the US took part in the study with the first patient enrolled in June 2013. For the patients who remain candidates for traditional surgical aortic valve replacement, the Perceval valve offers the potential benefit of shortening the time spent supported by the heart-lung machine. All this is performed without the need for sutures around the valve, thereby offering the possibility of shorter operative times, decreased complication rates, and use of minimally invasive approaches.

Sorin Group Announces FDA Clearance and First U.S. Implant of Memo 3D ReChord Annuloplasty Ring

Sorin Group announced the U.S. Food and Drug Administration (FDA) clearance for Memo 3D ReChord™, an innovative semi-rigid annuloplasty ring for mitral valve repair. The new Memo 3D ReChord, Sorin Group’s latest innovation in mitral valve repair, incorporates an innovative chordal guide system into the existing Memo 3D ring to simplify and standardize the approach to artificial chord replacement. Memo 3D ReChord’s unique design streamlines mitral repair procedures while allowing surgeons to obtain reproducible results even in advanced chordal reconstructions. Memo 3D ReChord‘s one-of-its-kind features include: A unique temporary chordal guide system that simplifies artificial chord replacement. Sorin's exclusive Carbofilm™ coating to enhance hemo-compatibility. Innovative cell-structure design to accommodate the mitral saddle shape while enabling the physiological 3D motion of the native annulus.

Sorin SpA Presents at Jefferies 2014 Global Healthcare Conference: London, Nov-20-2014 11:20 AM

Sorin SpA Presents at Jefferies 2014 Global Healthcare Conference: London, Nov-20-2014 11:20 AM. Venue: The Waldorf Hilton, Aldwych, London, United Kingdom.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SRN:IM €2.07 EUR +0.032

SRN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Edwards Lifesciences Corp $130.91 USD +1.52
Getinge AB kr206.20 SEK +19.60
Greatbatch Inc $50.16 USD +0.0099
InspireMD Inc $0.84 USD +0.0352
Stentys €5.09 EUR -0.03
View Industry Companies

Industry Analysis


Industry Average

Valuation SRN Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow 9.2x
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SORIN SPA, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at